Current topics in the diagnosis and treatment of scleroderma.
Scleroderma has been viewed as one of the most discouraging diffuse connective tissue diseases to manage. In the last 10 years, we have seen major advances in our understanding of its pathogenesis. New techniques for earlier diagnosis widen the window of opportunity for therapeutic intervention. A multitude of possible disease-modifying therapies are under study. Advances in molecular biology, including increased understanding of the cellular messages controlling the process of fibrosis, provide additional hope for better treatment. Clinical research in this disease is inhibited by limited numbers of patients and the difficulties encountered in evaluating progression and response to treatment. All patients with suspected or newly diagnosed scleroderma should be evaluated at a medical center actively engaged in the research of this disease. Such research is likely to accelerate the gains made during the last decade.
Barr
W G
WG
Section of Rheumatology, Loyola University Stritch School of Medicine, Maywood, Illinois.
D000328:Adult; D005260:Female; D006801:Humans; D009543:Nifedipine / Q000627:therapeutic use; D010396:Penicillamine / Q000627:therapeutic use; D012595:Scleroderma, Systemic / Q000175:diagnosis / Q000628:therapy*
D010396:Penicillamine; D009543:Nifedipine